LOGO
LOGO

Intraday Alerts

Chemours Falls 46% On FY23 Loss, Leadership Change

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Chemours Co. (CC) shares are declining more than 38 percent on Thursday morning trade, after the company expects net loss for the full year on reduced sales. Further, the company announced a CEO, CFO and other key executive change, amid an internal review.

Net loss for 2023 is estimated to be $225-$235 million, compared to profit of $578 million in the previous year.

Net sales decreased to $6.0 billion from $6.8 billion in 2022.

The company appointed Denise Dignam as the Interim CEO and Matt Abbott as the Interim CFO after President, CEO, CFO, Vice President, Controller, and Principal Accounting Officer were on administrative leave amid an internal review.

Currently, shares are at $15.77, down 46.99 percent from the previous close of $28.72 on a volume of 5,052,514.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Global Economics Weekly Update -June 15 - June 19, 2026

June 19, 2026 16:46 ET
Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.

RELATED NEWS